Bayer Oncology

About Bayer Oncology

A Radiopharma Developer player with a presence on the SNMMI floor; commercial activity worth a closer look.

Longer summary placeholder. Replace once Bracken finalizes the exhibitor profile copy.

What we're seeing

• BioPharma Reporter · 2026-02-11
  Bayer Oncology publishes dosimetry data at SNMMI 2026
  The work builds on more than a decade of radiochemistry collaboration.
• FierceBiotech · 2026-01-20
  Bayer Oncology closes Series C round to scale radiopharma manufacturing
  Coverage notes the company's growing footprint in the radioligand therapy space.
• Endpoints News · 2026-04-01
  Bayer Oncology partners with academic center on Actinium-225 program
  Industry observers expect more activity of this kind in the run-up to SNMMI 2026.
• Reuters Health · 2026-03-06
  Bayer Oncology files IND for next-generation PSMA-targeted agent
  The work builds on more than a decade of radiochemistry collaboration.
• PR Newswire · 2026-10-15
  Bayer Oncology announces Phase II readout for lead theranostic candidate
  The announcement comes amid tightening Mo-99 and Lu-177 supply.

Mocked while we wire the Exa integration. Headlines are illustrative.

What we expect to see at the booth

Booth talking points, demos, and announcements to watch for. Bracken analyst note coming.